Healthcare Industry News: IGRT
News Release - February 21, 2006
Accuray Expands Operations to Meet Growing Worldwide Demand for the CyberKnife(R) Robotic Radiosurgery SystemClinicians Around the World Embracing the CyberKnife System as an Essential Tool to Treat Tumors Anywhere in the Body
SUNNYVALE, Calif., Feb. 21 (HSMN NewsFeed) -- To meet the growing worldwide demand for the CyberKnife® Robotic Radiosurgery System, Accuray Incorporated, the global leader in the field of robotic radiosurgery, opened an expanded manufacturing facility in Sunnyvale, California. The facility immediately doubles Accuray's production capacity and is sized to support the company's growth over the next decade. In addition, the company strengthened its international presence by opening expanded regional offices in Paris, France and in Hong Kong to address the surge in sales and installations of the CyberKnife System worldwide.
"Accuray's global expansion is further evidence that the CyberKnife System is recognized as an essential tool in the fight against cancer, treating tumors anywhere in the body," said Euan S. Thomson, Ph.D., president and chief executive officer of Accuray. "We are committed to meeting the demand for the CyberKnife and to continue innovating, so that even more patients throughout the world can benefit from the most advanced robotic radiosurgery treatment available."
Accuray's decision to increase capacity is driven by the steady growth of the CyberKnife's use, particularly for extracranial tumors. Currently, over 50 percent of the CyberKnife System's total treatments in the U.S. are conducted on tumors outside the head. Growing clinical data and a record number of submissions for extracranial procedures at the recent CyberKnife Society Users' Meeting are evidence of the worldwide support of the CyberKnife System in treating tumors anywhere in the body, especially of the spine, lung, pancreas, liver and prostate.
Accuray's expanded manufacturing plant strengthens the company's R&D efforts. The new facility enables Accuray to accelerate the pace of product development and to continue to bring the latest innovations in robotic radiosurgery to current and future CyberKnife customers. Accuray also opened a new training center in February. The center is located in Accuray's corporate headquarters in Sunnyvale and allows the company to provide more clinicians with the critical information required to make radiosurgery an option for every cancer patient.
About the CyberKnife® Robotic Radiosurgery System
The CyberKnife System is the world's first and only radiosurgery system that utilizes intelligent robotics to treat tumors anywhere in the body. The CyberKnife System treats patients in single or staged (typically 2-5) sessions by delivering multiple beams of precisely directed radiation that converge upon the tumor while minimizing injury to surrounding healthy tissue. Image guidance and computer controlled robotics combine to continuously track, detect and correct for tumor and patient movements throughout the treatment with sub-millimeter accuracy. Because of this extreme precision and accuracy, no head or body frame is required. The CyberKnife has proven to attract a new patient population to a physician's practice and complements existing radiation therapy, IMRT or IGRT programs.
About Accuray Inc.
Accuray Inc., a privately held company based in Sunnyvale, Calif., is the global leader in the field of robotic radiosurgery. Its CyberKnife System is the world's first and only intelligent robotic radiosurgery system designed to treat tumors anywhere in the body with sub-millimeter accuracy. More than 100 CyberKnife Systems have been purchased by leading medical centers throughout the world and a large body of peer-reviewed papers supports its clinical practice. To date, the CyberKnife has treated more than 18,000 patients worldwide. For more information, please visit www.accuray.com.
For media inquiries, please contact Jeff Speer at firstname.lastname@example.org or 310-577-7870, ext. 156.
©2006 All rights reserved. Accuray, the Accuray logo, and CyberKnife are among trademarks or registered trademarks of Accuray Inc.
Issuer of this News Release is solely responsible for its
Please address inquiries directly to the issuing company.
Related News ItemsSwiss Medical Network Advances Cancer Care in Switzerland with Multi-System Agreement for Accuray Radiation Therapy Systems and RaySearch Oncology Software Systems
Accuray Launches Synchrony(R) Motion Tracking and Correction Technology for the Radixact(R) System
Phase 3 Randomized Trial Data Shows SBRT has Similar Acute Safety Profile to Conventional Radiation Therapy in Patients with Localized Prostate Cancer